Having entered the mature human erythrocyte, the malaria parasite survives and propagates within a parasitophorous vacuole, a membrane-bound compartment separating the parasite from the host cell cytosol. The bounding membrane of this vacuole, referred to as the parasitophorous vacuolar membrane (PVM), contains parasite-encoded proteins, but how these membrane proteins are trafficked to the PVM remains unknown. Here, we have studied the trafficking of PfExp1 to the PVM. We find that trafficking of PfExp1 to the PVM is independent of the folding state of the protein and also continues unabated upon inactivation of the PVM translocon Plasmodium Translocon of Exported proteins (PTEX). Our data strongly suggest that the trafficking of membrane proteins to the PVM occurs by as yet unknown mechanism, potentially unique to Plasmodium.
| INTRODUCTION
Common to many apicomplexans, during entry into their chosen host cell, malaria parasites surround themselves with a bounding membrane, referred to as the parasitophorous vacuolar membrane (PVM) (Lingelbach & Joiner, 1998) . Although the exact biological function of this membrane in blood stage parasites remains to be demonstrated, it appears to take part in several processes including nutrient transport to the parasite and protein transport from the parasite to the host cell. Supporting this, the PVM contains both host-and parasite-derived proteins (Bietz, Montilla, Külzer, Przyborski, & Lingelbach, 2009; Dluzewski, Fryer, Griffiths, Wilson, & Gratzer, 1989; Dluzewski et al., 1988; Dluzewski et al., 1992; Murphy et al., 2007; Repnik et al., 2015) . One of the first parasite-derived PVM proteins described is Plasmodium falciparum Exported Protein 1 (PfExp1, subsequently referred to as Exp1; Coppel et al., 1985; Kara et al., 1988; Simmons, Woollett, Bergin-Cartwright, Kay, & Scaife, 1987) . In both blood and liver stages, this essential protein is integrated into the PVM with the C-terminus exposed to the host cell cytosol and the N-terminus in the lumen of the parasitophorous vacuole (PV; Günther et al., 1991) . Although an alternate topology (N-terminus in the host cell cytosol) has also been suggested, this is not supported by any experimental data (Lisewski et al., 2014) . It has previously been demonstrated that Exp1 assumes a membrane-bound state cotranslationally in the ER (Günther et al., 1991) ; however, how this protein then integrates into the PVM has not been investigated.
Most research on protein traffic in the P. falciparum system have been focused on understanding how the parasite exports a large number of proteins across the PVM to the host erythrocyte, where they are involved in host cell modifications essential for parasite survival. We now know that many parasite proteins contain a trafficking signal, referred to as Plasmodium Export Element (PEXEL); host targeting motif. (HT) (Hiller et al., 2004; Marti, Good, Rug, Knuepfer, & Cowman, 2004) , that this signal is recognised and cleaved by an ER-resident protease (Plasmepsin V; Boddey et al., 2010; Russo et al., 2010) , and further that proteins pass across the PVM by passage through a parasite-encoded translocation machinery, PTEX (Beck, Muralidharan, Oksman, & Goldberg, 2014; de Koning-Ward et al., 2009; Elsworth et al., 2014b) . However, the route taken by PVM resident parasite proteins has not been investigated. Here, we have studied transport of the PVM protein Exp1 as an example to understand such a transport process. Exp1 is suitable for such as study as its topology and membrane-bound status is known from synthesis to final localisation at the PVM. Additionally, reagents are available for *Anke Tribensky and Andreas W. Graf are equal contributors. detection of endogenous Exp1, and its small size makes it possible to express Exp1-reporter constructs from an episome.
Based on knowledge of protein trafficking in both the Plasmodium and other systems, several models are possible to account for Exp1 transport ( Figure 1 ). It is generally accepted that, from the ER, Exp1 travels first to the parasite plasma membrane (PPM) by classical vesicle transport ( Figure 1a) . Once reaching the PPM, Exp1 is thus expected to expose the N-terminus to the lumen of the parasitophorous vacuole (PV), with the C-terminus remaining in the parasite cytosol. Exp1 must then somehow cross the hydrophilic PV and be inserted into the PVM (Figure 1a ). The simplest model of this transport step supposes that vesicles then bud from the PPM and carry Exp1 in a membrane-bound state to the PVM (Figure 1b) . This model is supported by topological considerations (as a vesicle-based transport step would result in the observed topology at the target membrane), ultrastructural reports showing potential vesicles within the PV (Cooke, Lingelbach, Bannister, & Tilley, 2004; Olliaro & Castelli, 1997) . Additionally, as the PVM expands during parasite development, it is likely that some membrane transports from the parasite to the PVM must take place.
On the other hand, vesicular transport generally requires a complement of accessory proteins to regulate membrane budding, fusion, and directionality, none of which have yet been detected in the PV.
Additionally, the small distance between the PPM and PVM may be restrictive to membrane budding and fusion events. A second model supposes that Exp1 is extracted from the PPM, possibly with the aid of molecular chaperones, and transported to and inserted into the PVM, also with the potential aid of accessory factors (Figure 1c ; Haase & de Koning-Ward, 2010) . Posttranslational insertion of membrane proteins is a well-recognised phenomenon in other systems and is known to play a role in (for example) insertion of proteins into the mitochondrial inner membrane (Dudek et al., 2015; Herrmann & Neupert, 2003) . However, extraction of a trans-membrane protein from a lipid bilayer is a (as regards to literature) rare event and likely to be bioenergetically unfavourable (Cymer, von Heijne, & White, 2015) . Also, no soluble form of Exp1 has yet been detected, although this may have technical reasons. Recent data from Mesén-Ramírez and colleagues, and supported by previous studies by Grüring et al.
on trafficking of PEXEL-negative exported protein (PNEPs) to the host cell also reveal on possible further model (Figure 1d ) (Gruring et al., 2012; Mesén-Ramírez et al., 2016) . Similarly to the previous model, this suggests that Exp1 could leave the PPM and traffic across the PV in a soluble, possibly chaperoned state. In contrast to model C, membrane extraction takes place with the aid of a hypothetical pore within the parasite plasma membrane, and upon reaching the target membrane, Exp1 could insert with the aid of the vacuolar translocon PTEX (de Koning-Ward et al., 2009; Elsworth, Crabb, & Gilson, 2014a; Elsworth et al., 2014b) . In this case, PTEX acts in a similar fash- (e) PTEX-assisted transport from PPM to PVM. Under each model is shown the predictions for involvement of either protein unfolding or PTEX function. Green, likely to be involved; red, not likely to be involved. RBCC, red blood cell cytosol; PV, parasitophorous vacuole; PC, parasite cytosol; ER, endoplasmic reticulum the PPM before inserting them into the PVM (Elsworth et al., 2014a) .
Inactivation of PTEX appears to block translocation of exported membrane proteins to the host cell cytosol, but it is so far unclear whether this is due to a lack of membrane extraction (as would be the case in Figure 1e ) or due to a lack of translocational and membrane integrase activity (as would be the case in Figure 1d ; Elsworth et al., 2014b) .
Of importance for the purposes of this current study, dependence of Exp1 transport on either protein unfolding or PTEX functionality can be used to distinguish between each of the above models. Additionally, this strategy allows us to address whether traffic of proteins to the PVM occurs in a similar manner to that of membrane-bound PEXEL or Pexel-negative Exported (PNE) proteins exported to the host cell (which requires both PTEX and protein unfolding; Mesén-Ramírez et al., 2016; Gehde et al., 2009) . In this study, we have investigated the transport of Exp1 to the PVM using both the murine dihydrofolate reductase (mDHFR) system (Gehde et al., 2009 ; to look at the role of protein unfolding) and two established cell lines in which PTEX function has been disrupted (Beck et al., 2014; Elsworth et al., 2014b ; to examine the importance of PTEX).
Using a reporter consisting of full-length Exp1 fused to mDHFR and green fluorescent protein (GFP), we convincingly demonstrate that transport of Exp1 to, and insertion into, the PVM is independent of protein unfolding events. Furthermore, inactivation of the PTEX components PTEX150 and Hsp101 had no effect on Exp1 transport to the PVM. Our data consequently exclude a role of either PTEX or protein unfolding in integration of native PVM membrane proteins.
This suggests that further, as yet uncharacterized, transport mechanisms must exist to allow integral PV membrane proteins such as Exp1 to reach the end of the line at the PVM.
2 | RESULTS 2.1 | An Exp1-mDHFR-GFP reporter folds in response to addition of folate analogues
We, and others, have previously demonstrated that the mDHFR can be used to elucidate the importance of protein folding during export of proteins to the host cell, likely due to interference with either engagement of, or traffic through the vacuolar translocon (Gehde et al., 2009; Gruring et al., 2012; Mesén-Ramírez et al., 2016; Riglar et al., 2013) .
We were interested in investigating whether Exp1 requires protein unfolding to integrate into the PVM. We therefore generated a transgenic parasite line expressing a chimeric reporter containing full-length were then analysed by immunoblotting using anti-GFP. T = 0 refers to time point 0, other times in hours. Size markers in kDa localisation. Transgenic parasites expressed a fusion protein of approximately 70 kDa, close to the predicted molecular mass for the chimera (   Figure 2b ). To examine the further suitability of this reporter for our purposes, we carried out a proteinase protection assay. Addition of folate analogues (such as WR99210 used in this study) generally leads to folding of mDHFR and insensitivity to protease digestion. We have previously shown that addition of exogenous protease is unnecessary for this assay, as endogenous parasite-derived proteases can also degrade unfolded mDHFR (Gehde et al., 2009 ). We isolated erythrocytes infected with mid-trophozoite stage 3D7 EDG parasites and lysed the erythrocytes with tetanolysin (Ansorge, Benting, Bhakdi, & Lingelbach, 1996) to remove host hemoglobin. The resulting parasite pellet was hypotonically lysed then incubated for various times in the presence or absence of various additives. As a negative control, one sample was incubated in the presence of protease inhibitor cocktail.
After incubation, western blotting using anti-GFP antibodies was used to visualise proteolysis over time. In the sample incubated with WR99210 (WR), one band at the expected molecular mass of the full-length reporter could be detected after 2 hr incubation (Figure 2 b, T = 2) and additionally, a band corresponding to the molecular mass of the mDHFR and GFP alone. The situation in samples incubated without WR appeared initially similar at T = 2, but over time, it became evident that samples incubated without WR were degraded more quickly (T = 4) and eventually, totally (T = 6). In contrast, even after 6 hr of incubation, samples incubated with WR still exhibited a strong mDHFR and GFP band. In all cases, addition of protease inhibitors leads to preservation of the full-length chimera (Figure 2b ). These data demonstrate that, even in the context of an Exp1-mDHFR-GFP fusion, mDHFR is able to bind to WR and that this binding leads to a conformational change in mDHFR structure and thus resistance to proteolysis.
| Trafficking of Exp1-mDHFR-GFP appears unaltered in live cell imaging by addition of WR
Our chimeric reporter contained a C-terminal GFP moiety, thus we could follow trafficking to the PVM upon stabilisation of mDHFR by WR. To ensure that the resulting fluorescence distribution was purely due to newly synthesised reporter (and not previously trafficked before stabilisation of mDHFR), we added WR and allowed the parasite to reinvade new erythrocytes. A culture containing mid-trophozoite stage-infected erythrocytes was split into two plates that were subsequently incubated for one cycle (44 hr) in either the presence of absence of WR. In both cases, GFP fluorescence could be detected in a ring-like structure surrounding the parasite, consistent with trafficking to the PVM (Figure 3 ).
This experiment shows that, at least at the level of fluorescence microscopy, stabilisation of the mDHFR moiety of the reporter does not lead to any obvious block in trafficking to the PVM.
2.3 | Subcellular permeabilisation followed by protease protection verifies insertion of Exp1-mDHFR-GFP in the PVM, independent of protein-folding status 2.4 | PTEX150, an essential component of the PTEX translocon, is not required for insertion of endogenous Exp1 into the PVM As mentioned above, it had been speculated that PTEX may insert nonexported transmembrane (TM) proteins into the PVM (Haase & de Koning-Ward, 2010; Elsworth et al., 2014b; Spielmann & Gilberger, 2015) . To investigate whether Exp1 is trafficked in this manner, we studied insertion of Exp1 into the PVM in cell lines in which levels of the essential PTEX component PTEX150 can be downregulated using a glmS riboswitch system (Elsworth et al., 2014b) . Synchronized parasite cultures at 20-24 hr post invasion (hpi) containing either the PTEX150-HAglmS or were left untreated, or grown in the presence of 1 mM glucosamine (glmS line) until 16 hpi in the next cycle. Infected erythrocytes were then permeabilised with tetanolysin (which, similar to SLO, lyses only the erythrocyte plasma membrane, allowing access of protease to the PVM). To verify the fractionation procedure, we detected HsHsp70 (a marker of the host cell cytosol) and PfAldolase (a marker of the parasite cytosol). We initially attempted to use PfSERP as a marker for the PV lumen, however we were not able to detect this protein in the early stage parasites analysed. For this reason, we instead used PfPV1 as a marker for the PV lumen (Nyalwidhe & Lingelbach, 2006) . All three markers were found only in the expected fraction ( Figure 5a ). Furthermore, we verified downregulation of PTEX150 using specific antisera. In the PTEX150-HAglmS cell line grown in the presence of 1 mM glucosamine, expression of PTEX150 was greatly reduced when compared to nontreated cells (Figure 5a ).
Using the permeabilised cells from above, we carried out a protease protection assay followed by western blotting using antisera raised against the C-terminus of Exp1 to determine whether endogenous Exp1 had been correctly inserted into the PVM. Exp1 was sensitive to proteinase K treatment both in cells that maintained a functional PTEX complex and in cells in which PTEX function has been inhibited ( Figure 5b ). To verify that downregulation of PTEX150 leads to a block in PTEX function (and thus protein export capacity), we analysed by immunofluorescence the localisation of the exported proteins knobassociated histidine rich protein (KAHRP) and skeletal binding protein (SBP1). In both cases, downregulation of PTEX150 led to a block of protein export and an accumulation of the protein around the parasite itself ( Figure S1a ).
This assay demonstrates that, even without an active PTEX complex, endogenous Exp1 is still capable of inserting into the PVM. This assay demonstrates that, even without the chaperone and unfolding activity of Hsp101, endogenous Exp1 is still efficiently inserted into the PVM.
| DISCUSSION
The malaria parasite P. falciparum expends considerably resources to modify the host erythrocyte to its needs, with almost 10% of the entire proteome dedicated to this process (Hiller et al., 2004; Marti et al., 2004; Sargeant et al., 2006) . While many of these proteins are exported into the host cell, others are inserted into the PVM that surrounds the parasite during invasion. Although protein traffic to the host cell has been studied in detail in the past decade, how proteins reach the PVM has been widely discussed but not experimentally interrogated. Here, we have, for the first time, tested various transport models suggested to allow transport of integral membrane proteins to the PVM. Using Exp1 as our model and applying various cell biological, genetic, and biochemical tools, we are able to partially characterise the transport pathway of this protein from genesis at the parasite's ER to its final localisation as an integral membrane protein within the PVM.
One prerequisite for several of the transport models so far suggested is the requirement for unfolding (either partial or total) of PfExp1. In Figure 1 , models C, D, and E all require unfolding of at least part of the protein. Similarly, in model C, D, and E, the C-terminus of Exp1 is required to passage across the lipid bilayer. Although such . Cells were then permeabilised with tetanolysin as previously and separated into pellet (P) and supernatant (S) fractions. As previously, all fractions were then analysed for the presence of markers for the erythrocyte cytosol (HsHsp70), PV (PV1), and parasite cytosol (aldolase). As a control for cells numbers, we analysed the distribution of the host cell protein glycophorin (Glyco). Additionally, we monitored downregulation of PTEX150 using specific antisera. (b) Protease protection to analyse the localisation and topology of endogenous Exp1. Permeabilised cells (pellet fraction, from A. above) were incubated with the additives noted and then protein extracts analysed using antibodies against Exp1. As a control for cells numbers and cell damage, we also analysed the parasite cytosol marker aldolase. Size markers in kDa posttranslational membrane insertion has been described in several systems, all substrates so far studied are required to be maintained in a "translocation competent" (i.e., unfolded) state for successful membrane integration, and introducing a folded protein domain leads to lack of, or only partial, membrane integration (Borgese & Fasana, 2011; Jores et al., 2016; Schlenstedt, Zimmermann, & Zimmermann, 1994) . Our experimental chimera contained not only the native Cterminus of PfExp1 but also mDHFR and GFP. Although GFP itself generally requires some time to fold into its stable beta barrel conformation, we have previously shown that mDHFR can be used to block transport of exported proteins within the PV, thus showing that mDHFR has opportunity to fold already in the secretory pathway and, if stabilised, arrives at the PV in a folded conformation. We therefore think it unlikely that PfExp1 inserts into the PVM as shown in model C. Additionally, a folded mDHFR (or other) domain has been shown to inhibit passage through the putative PPM or PTEX translocons, depending on the length of the domain preceding the conditionally foldable domain (Gruring et al., 2012; Mesén-Ramírez et al., 2016) . Therefore, models D and E are also improbable, as they would require passage of folded mDHFR through this complex. It should be noted that previous studies used exported proteins, and it is unclear if the same rules apply for resident PVM proteins.
A major chokepoint for protein transport to the host cell (both of PEXEL and PNE proteins) is the vacuolar translocon PTEX (de Koning-Ward et al., 2009) . So far, it appears that, regardless of which signals are directing transport, exported proteins converge at this complex for passage across the PVM (Elsworth et al., 2014b; Gruring et al., 2012) . As PTEX has been suggested as a potential gateway for protein insertion into the PVM, possibly due to a secondary function as a protein membrane insertase (Elsworth et al., 2014a; Haase & de Koning-Ward, 2010; Mesén-Ramírez et al., 2016) , we studied the effect of inactivating PTEX activity on Exp1 transport.
Although we were able to demonstrate lack of PTEX activity in both of the cell lines herein studied, we observed no detectable block in Exp1 insertion into the PVM. Transport through PTEX requires at least partial protein unfolding, and a folded mDHFR cannot be translocated (Gehde et al., 2009; Gruring et al., 2012; Riglar et al., 2013) . That stabilisation of our Exp1-mDHFR-GFP reporter did not lead to a block in trafficking to the PVM further rules out involvement of PTEX. While we cannot formally exclude that PTEX, subcomplexes exist with different biological activities, with PTEX150 and Hsp101 being nonessential for membrane integration; so far, such subcomplexes have not been described in the literature. Our data strongly suggests that PTEX, as currently understood, is unable to act as a membrane integrase for PVM proteins. One possibility that our data cannot exclude is the presence of a second vacuolar translocation complex of so far unknown molecular composition. If such a complex were able (similar to the bacterial TAT translocon) to translocate folded protein domains (such as DHFR) across a biological membrane, our data would also be consistent with such a mechanism. However, as such an alternative
translocon has yet to be described in malaria parasites, we wish to initially exclude such a mechanism due to lack of experimental evidence.
During invasion of the host cell, specialised organelles such as rhoptries and micronemes discharge their contents into the host cell, helping to complete invasion and also expanding the nascent PVM. It is therefore conceivable that Exp1 may be introduced together with components of the prePVM and therefore must not traffic across the PV. Our previous data on PfExp1 expression (Kulzer et al., 2010) and available datasets on mRNA abundance (PlasmoDB) appear to suggest that maximal Exp1 expression occurs in early-to-mid trophozoite and not late troph/schizont stages as would be expected for a protein required for invasion, or directly following entry to the new host cell.
Consequently, native Exp1 synthesised during the trophozoite stage is required to cross the PV before gaining access to the PVM.
Shortly, after it was demonstrated that Exp1 is synthesised as an integral membrane protein, it was realised that its transport constituted an unusual cell biological phenomenon, and it was suggested that such transport must take place by vesicular transport across the PVM, despite the lack of any evidence for such a process (Günther et al., 1991; Lingelbach, 1993) . Our data, while not providing direct support for such a process, are able to exclude other suggested transport mechanisms. Further studies will be required to elucidate the exact nature of Exp1 transport.
Generally, traffic of proteins so specific subcellular localisations is a signal-driven process. Exp1, apart from an ER-type hydrophobic N- 
| Parasite cultivation and transfection
Clone 3D7 parasites were maintained in O+ erythrocytes (University of Marburg Blood bank) as previously described (Trager & Jensen, 1976) . Ring-infected erythrocytes were transfected as previously described and selected using 4 μg ml −1 blasticidin (Invivogen [Mamoun, Gluzman, Goyard, Beverley, & Goldberg, 1999] ). PTEX150-HAglmS and Hsp101 DDD cell lines were maintained as previously described (Beck et al., 2014; Elsworth et al., 2014b (Rossner & Yamada, 2004) .
| Cell fractionation, protease protection, and western blotting
Trophozoite stage-infected erythrocytes were harvested by Gelafundin floation (Pasvol, Wilson, Smalley, & Brown, 1978) and permeabilised using four hemolytic units of either streptolysin O or tetanolysin as previously described (Ansorge et al., 1996; Külzer, Bittl, & Przyborski, 2015) . Protease protection to assess stability of the GFP chimera was carried out as previously described (Gehde et al., 2009) .
Protease protection to assess transport of and topology of Exp1 to and in the PVM was carried out as previously described (Külzer et al., 2015) . Protein extracts (1 × 10 7 cell equivalents/lane) were analysed by SDS-PAGE and immunoblotting using mouse anti-GFP (1:1000, Roche), rabbit anti-PfSERP (1:500; Ansorge et al., 1996) , rabbit antiPfAldolase (1:5000; Ansorge et al., 1996) , rabbit anti-PfPV1 (1:500; Nyalwidhe & Lingelbach, 2006) , mouse anti-Glycophorin (1:1000, Sigma), mouse anti-HsHsp70 (1:500, Santa Cruz), rabbit anti-PfExp1
(1:500; Günther et al., 1991) , and suitably conjugated secondary antibodies (1:2000, DAKO).
